Arena Pharma initiates pulmonary hypertension drug clinical study
Arena Pharmaceuticals has initiated dosing in a Phase I clinical trial of APD811, its novel drug candidate which targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension (PAH).
The double-blind, randomised, placebo-controlled Phase I will enroll up to 72 healthy adult volunteers and is designed to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD811.
Arena Pharma senior vice president and chief medical officer, William Shanahan said that an orally bioavailable prostacyclin receptor agonist could improve the standard of care for patients with PAH.
"APD811 is a non-prostanoid compound; in preclinical studies, the oral uptake, half life and efficacy characteristics suggest that it could offer improved administration over current prostacyclin receptor therapies," Shanahan added.
APD811 is a potent and selective agonist of the prostacyclin receptor, which regulates the vascular smooth muscle tone to improve mortality and exercise tolerance in PAH patients.
Related Insight
Suppliers Directory
Penn Pharma - Drug Development, Clinical Supplies & Contract Manufacturing Solutions
Penn Pharma is a leading provider of fully integrated and cost effective pharmaceutical development, clinical supply and manufacturing and packing services to the international healthcare industry, whose services support a fast and effective route from clinic to market. Penn provides unparalleled service offerings developed over its 30 year trading history.
Contract Research & Services > Clinical Trials > Suppliers
Animascope - Preclinical Imaging Services
Animascope is a company providing multimodality imaging services to international customers. Animascope experts have several years of experience in discovery and preclinical imaging in vivo.
Contract Research & Services > Clinical Trials > Suppliers
Synevo Central Lab - Clinical Laboratories
Synevo Central Lab is a full service European central laboratory providing comprehensive clinical laboratory services for pharmaceutical and biotechnological companies.
Contract Research & Services > Clinical Trials > Suppliers
Durbin - Comparator and Ancillary Supply for Clinical Trials
Durbin combines its heritage of over 45 years of sourcing and distributing specialist pharmaceuticals around the world with a commitment to partnership, working to bring a real difference to the provision of clinical trial comparators and ancillaries.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Clinical Trials > White Papers
Licensing Agreement League Table of Legal Advisors Q1 2010
Published by BioPharm Insight PBR
Contract Research & Services > Clinical Trials > White Papers
Additional Products and Services
Published by PFC Pharma Focus
Contract Research & Services > Clinical Trials > White Papers
Win with Networked Drug Development Alliances
Published by INC Research
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.